AEON Biopharma Inc. Class A (AEON)
NYSE: AEONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AEON stock chart
Technical analysisKey statistics
All statistics- Market cap
- $10.35M
- EPS (TTM)
- -$3.89
- Dividend yield
- None
- 52-week range
- 0.106 – 1.45
- Day range
- 0.1218 – 0.1346
- Volume / Avg
- 1.17M / 7.44M
- Beta
- —
- Shares outstanding
- 84.12M
52-week range
AEON stock today
AEON Biopharma (AEON) closed at $0.123 on Nov 20, down 7.59% (-$0.0101), versus the S&P 500's 3.70% decline. Trading was light, with 1.17M shares changing hands, about 16% of the average daily volume. Shares are 91.5% below their 52-week high of $1.45, set on Feb 23, 2026 and 16.0% above the 52-week low of $0.106, near the bottom of the past year's range.
AEON is down 88.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 85.2%. AEON Biopharma has posted a net loss over the last twelve months (EPS of -$3.89), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About AEON Biopharma
Company profileAEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert Bancroft
- Headquarters
- Irvine, CA
- Employees
- 8
- Website
- aeonbiopharma.com
Financial highlights
Full financialsAEON Biopharma reported a net loss of $39.2 million, compared with net income of $42.0 million a year earlier. Diluted earnings per share came in at -$3.95, down from $72.93.
| Fiscal year | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Growth | — | — | — | — |
| Net income | $-39.22M | $42.01M | $-52.56M | $8.20M |
| EPS (diluted) | $-3.95 | $72.93 | $-0.38 | — |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$1.82+1379.67%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.01 vs $-0.10
- Surprise
- +90.00%
AEON news
All AEON news- Priveterra Acquisition Corp. II Reports Third Quarter 2026 Financial ResultsNasdaq
- AEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450GlobeNewswire
- Priveterra Acquisition Corp. II Amends Milestone Warrants to Reduce Exercise PriceNasdaq
- AEON Biopharma, Inc. Details ABP-450 Biosimilar Strategy and Plans Q4’26 IND SubmissionNasdaq
- AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711GlobeNewswire
AEON Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ASBPAspire-Lakewood Holdings Inc. | 7.13 | -5.44% | $10.00M | vs AEON |
| RADXRadiopharm Theranostics Limited ADR | 0.6304 | -9.71% | $9.90M | vs AEON |
| CMMBChemomab Therapeutics Ltd. ADR | 1.19 | +4.39% | $9.58M | vs AEON |
| BFRIBiofrontera Inc. | 0.53 | -7.02% | $9.51M | vs AEON |
| GDTCCytoMed Therapeutics Limited | 0.755 | -2.33% | $9.01M | vs AEON |
| CALCCalciMedica Inc. | 1.26 | +7.69% | $8.69M | vs AEON |
| OPTHOptimi Health Corp. | 1.51 | -13.71% | $8.65M | vs AEON |
| BIVIBioVie Inc. Class A | 0.80 | -12.07% | $8.58M | vs AEON |
Indexes, lists and sector
AEON Biopharma stock FAQ
What is AEON Biopharma's stock price today?
AEON last traded at $0.123 as of Nov 20, 4:00 PM EST, down 7.59% on the day. Prices are delayed at least 15 minutes.
Does AEON Biopharma pay a dividend?
No. AEON Biopharma does not currently pay a regular cash dividend.
Who is AEON Biopharma's CEO?
Mr. Robert Bancroft is the chief executive officer of AEON Biopharma Inc. Class A, which has about 8 employees.
Has AEON ever split its stock?
Yes. The most recent AEON stock split was a 1-for-72 split on Feb 26, 2025.
What is the AEON 52-week high?
The 52-week high for AEON is $1.45 and the 52-week low is $0.106. The stock is currently 91.5% below its high.